Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 15 Apr 2008

von Wyl Viktor, Yerly Sabine, Böni Jürg, Bürgisser Philippe, Klimkait Thomas, Battegay Manuel, Bernasconi Enos, Cavassini Matthias, Furrer Hansjakob, Hirschel Bernard, Vernazza Pietro L, Rickenbach Martin, Ledergerber Bruno, Günthard Huldrych F

Abstract excerpt

BACKGROUND: The human immunodeficiency virus type 1 reverse-transcriptase mutation K65R is a single-point mutation that has become more frequent after increased use of tenofovir disoproxil fumarate (TDF). We aimed to identify predictors for the emergence of K65R, using clinical data and genotypic resistance tests from the Swiss HIV Cohort Study. METHODS: A total of 222 patients with genotypic resistance tests...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Anti-HIV Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antiretroviral Therapy, Highly Active

Share to HIV Reverse Transcriptase

Share to Logistic Models

Share to Organophosphonates

Share to Point Mutation

Share to Tenofovir

Source

Identifiers

PMID: 18444871
DOI: 10.1086/528863

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.PMID 18444871Read ↗

Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir.Semantic proximity Read ↗

The K65R Mutation in HIV-1 Reverse Transcriptase: Genetic Barriers, Resistance Profile and Clinical ImplicationsSemantic proximity Read ↗

The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.Semantic proximity Read ↗

HIV-1 reverse transcriptase (RT) genotypic patterns and treatment characteristics associated with the K65R RT mutation.Semantic proximity Read ↗

Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations.Semantic proximity Read ↗

K65R, TAMs and tenofovir.Semantic proximity Read ↗

The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.Semantic proximity Read ↗

The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of tenofovir.Semantic proximity Read ↗

K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.Semantic proximity Read ↗

High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen.Semantic proximity Read ↗

Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine.Semantic proximity Read ↗

A rare HIV reverse transcriptase mutation, K65N, confers reduced susceptibility to tenofovir, lamivudine and didanosine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.